article Open AccessTop 1% cited
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
New England Journal of Medicine · 2009 · Vol. 361(10) · pp. 947–957
Tony Mok✉(Chinese University of Hong Kong)Yi‐Long WuSumitra Thongprasert(Chiang Mai University)James Chih‐Hsin Yang(National Taiwan University Hospital)Da-Tong Chu(Chinese Academy of Medical Sciences & Peking Union Medical College)Nagahiro Saijo(National Cancer Center Hospital East)Patrapim Sunpaweravong(Prince of Songkla University)Baohui Han(Shanghai Chest Hospital)Benjamin Margono(Universitas Dr. Soetomo)Yukito Ichinose(National Hospital Organization Kyushu Cancer Center)Yutaka Nishiwaki(National Cancer Center Hospital East)Yuichiro Ohe(Tokyo National Hospital)Jin-Ji Yang(Guangdong General Hospital)Busyamas Chewaskulyong(Chiang Mai University)Haiyi Jiang(AstraZeneca (Japan))Emma Duffield(AstraZeneca (United Kingdom))Claire Watkins(AstraZeneca (United Kingdom))Alison Armour(AstraZeneca (United Kingdom))Masahiro Fukuoka(Kindai University)
Abstract
Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia. The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib. (ClinicalTrials.gov number, NCT00322452.)
Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and TreatmentGefitinibMedicineCarboplatinHazard ratioInternal medicinePaclitaxelOncologyLung cancerClinical endpointPopulation
MeSH terms
GefitinibAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedMutationQuinazolines
Citations
8,201
FWCI
401.73
field-weighted impact
References
32
Percentile
100%
vs. same field & year
Citations per year
Cited by
Targeting RTK Signaling Pathways in Cancer
Cancers · 2015 · 375 citations
Frequent and Focal <i>FGFR1</i> Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Science Translational Medicine · 2010 · 821 citations
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Science Translational Medicine · 2011 · 3,534 citations
The prevalence of <i>EGFR</i> mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Oncotarget · 2016 · 768 citations
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Journal of Clinical Oncology · 2013 · 3,181 citations
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Clinical Cancer Research · 2016 · 1,214 citations
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Clinical Cancer Research · 2012 · 1,115 citations
References
Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
Biometrics · 1975 · 2,349 citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine · 2004 · 11,455 citations
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Proceedings of the National Academy of Sciences · 2004 · 4,332 citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
JNCI Journal of the National Cancer Institute · 2000 · 15,689 citations
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
JNCI Journal of the National Cancer Institute · 2005 · 2,385 citations
Mutations of the <b> <i>Epidermal Growth Factor Receptor</i> </b> Gene in Lung Cancer
Cancer Research · 2004 · 1,225 citations
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Science · 2004 · 9,380 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.